Allogeneic HCT Feasible in Older Patients With Myelodysplastic Syndrome
By Elana Gotkine HealthDay Reporter
WEDNESDAY, July 23, 2025 -- Allogeneic hematopoietic cell transplantation (allo-HCT) is feasible in older patients with myelodysplastic syndrome (MDS), according to a study published online June 26 in the European Journal of Haematology.
Fernando Barroso Duarte, Ph.D., from Walter Cantídio University Hospital in Fortaleza, Brazil, and colleagues conducted a retrospective multicenter study to compare outcomes and assess risks associated with allo-HCT in patients with MDS aged 65 years and older versus younger than 65 years across 38 transplant centers in Latin America from 1988 to 2023. A total of 441 patients were enrolled; 16 percent were aged 65 years and older.
The researchers found that overall survival (OS) was 49.3 and 56.7 percent in patients 65 years and older and those younger than 65 years, respectively, at five years, and progression-free survival (PFS) was 48.4 and 56.2 percent, respectively. The cumulative incidence rates of relapse and nonrelapse mortality were 13.6 and 33.8 percent, respectively. No significant differences were seen between the age groups in OS, nonrelapse mortality, or PFS after propensity score matching. There was an association seen between PFS in patients aged 65 years and older with high-risk Revised International Prognostic Scoring System stratification. A higher risk for relapse was seen for patients aged 65 years and older compared with those aged younger than 65 years. Prevalence risk was associated with male sex, reduced-intensity conditioning, mobilized blood cells, and prior treatment in patients aged 65 years and older, while in those aged younger than 65 years, associations were seen with complications and chronic graft-versus-host disease.
"Allo-HCT is feasible in elderly patients with MDS, with no significant differences in OS or mortality risk compared to younger patients," the authors write. "However, age may influence disease progression in very high-risk elderly patients with MDS, as well as the risk of relapse after transplantation. We identified that male sex, the use of a reduced-intensity conditioning regimen, and a mobilized blood cell graft are prevalent risk factors associated with elderly patients with MDS undergoing HCT."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Inflammation and Nutrition-Based Scores Tied to Prognosis of Low-Risk Myelodysplastic Syndrome
THURSDAY, July 24, 2025 -- The Prognostic Nutritional Index (PNI) and systemic oxidative stress (SOS) score are independently associated with poorer prognosis of low-risk...
Infection Tied to One-Fourth of Deaths With Lower-Risk Myelodysplastic Syndromes
TUESDAY, April 22, 2025 -- Roughly one in 14 people with lower-risk myelodysplastic syndromes (LR-MDS) have an infection in the first year after diagnosis, according to a study...
AI Improves Risk Prediction in Patients With Myelofibrosis Undergoing Allo-HCT
FRIDAY, April 4, 2025 -- For patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation (allo-HCT), machine learning (ML) enhances risk stratification...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.